Table 1.

ESCAT levels of genomic alterations according to the ESMO Clinical Practice Guideline for biliary tract cancer (16).

Gene	Alteration	Prevalence	ESCAT
IDH1	Mutations	20%	IA
FGFR2	Fusions	15%	IB
BRAF V600E	Mutations	5%	IB
	MSI-H/dMMR	2%	IC
NTRK	Fusions	2%	IC
ERBB2	Amplifications Mutations	10% 2%	IC –
PIK3CA	Mutations	7%	IIIA
BRCA 1/2	Mutations	3%	IIIA
MET	Amplifications	2%	IIIA